The Patent Cliff Sparks a Biotech Land Grab
Several of the pharmaceutical industry's largest products lose exclusivity late this decade, while internal research productivity remains uneven. Cash-rich drugmakers therefore need acquisitions, licensing deals and royalty structures to replace revenue faster than conventional discovery can deliver. Biotechs with validated platforms, late-stage assets or commercially de-risked drugs gain negotiating leverage, as do contract manufacturers serving complex biologics. Incumbents with concentrated patent cliffs risk earnings compression or value-destructive dealmaking.
How this story could end...
The endings this story genuinely supports, written from the same evidence as the story updates. The value ranges are illustrative examples of how the affected companies as a group could re-rate — not forecasts, targets or advice.
Mapping out the endings…
How the two sides have traded
The bull and bear baskets for this story, equal-weighted and indexed so the two lines start together.
Each scenario's basket — 3 months
Both sides on one chart — 10 stocks on the bull side, 10 stocks on the bear side. Neither side is emphasised.
Each line tracks the 10 companies most exposed to this story, so a broad basket of loosely related names does not flatten it. The full list below is unchanged.
Jul 20, 2026 – Oct 19, 2026 · 66 sessions
Equal-weighted performance of the 10 most exposed stocks over the last 3 months.
No data for 603259.SS, RGEN, ROG.SW, NBIX, MDGL, CYTK, SOBI.ST, BANB.SW, RVMD, KRYS, ZEAL.CO, SRT3.DE, GILD, BHC.TO
Most affected stocks
Bull case
Genmab combines validated antibody platforms, royalty income and wholly owned oncology assets, giving it leverage in licensing and acquisition negotiations.
Thermo Fisher earns from research tools, clinical services and manufacturing regardless of which external drug candidates win.
Its validated antibody engine, profitable commercial portfolio and broad late-stage pipeline make Regeneron a strategically valuable partner even if its scale limits takeover feasibility.
Demand for outsourced production of antibodies and other complex biologics should rise as acquirers seek to scale newly purchased pipelines quickly.
Lonza benefits as acquired biologics and advanced therapies require complex development and outsourced manufacturing capacity.
Its expanding biologics CDMO network is positioned to capture outsourced development and manufacturing work generated by pipeline acquisitions.
Exelixis combines cash flow from an established cancer drug with a pipeline that could attract licensing or acquisition interest.
Sandoz can monetize the other side of the patent cliff through biosimilars and complex generics as blockbuster biologics lose exclusivity.
Royalty Pharma provides non-dilutive capital to biotech developers and benefits when pharmaceutical companies compete for external innovation.
Biotech financing recoveries and pressure to generate acquisition-grade clinical data support demand for Medpace's clinical-trial services.
Bear case
Bristol Myers faces overlapping exclusivity losses across major products, increasing pressure to acquire growth at potentially expensive valuations.
Patent erosion in major pharmaceutical franchises collides with balance-sheet and litigation constraints, limiting Bayer's ability to compete freely for scarce replacement assets.
Late-decade intellectual-property pressure on key HIV products raises the urgency for GSK to replenish revenue through business development and pipeline execution.
Generic erosion of Entresto and other mature products increases Novartis's reliance on acquisitions and externally sourced innovation to sustain growth.
AstraZeneca must offset approaching exclusivity losses across several major medicines, creating pressure to keep buying or licensing increasingly expensive late-stage assets.
A mature product portfolio, looming exclusivity losses and significant leverage constrain Organon's ability to buy enough growth to offset erosion.
Johnson & Johnson faces biosimilar erosion in key medicines and must sustain pipeline productivity across a very large pharmaceutical base.
Approaching exclusivity losses in core neuropsychiatric products leave Otsuka dependent on successful launches, licensing and acquisitions to replace concentrated revenue.
Erosion in mature neurological franchises and uneven internal pipeline execution leave Biogen under pressure to license or acquire new growth assets.
Astellas remains dependent on successfully replacing mature blockbuster revenue through a pipeline with meaningful execution risk.
Reporting behind this story
Looking at what moved this story…